LEXAPRO: $4.25 Billion in new profits - How many dead children???????

[Guest guest]

A

Thu, 2 Mar 2006 20:38:27 EST

LEXAPRO: $4.25 Billion in new profits - How many dead

children???????

 

 

 

Just this past year we got black box warnings on the harmful effects of

antidepressants upon children, even to the extent of doubling the

suicide rate in this age group.

 

But apparently the FDA suffers from severe memory loss because they have just

given a 2 1/4 year extension on the Lexapro patent for Forest Labs testing this

deadly antidepressant, Lexapro, upon CHILDREN!!!

 

Can someone give me any logical excuse for that other than $$$$$$$$??

 

This is the exact same reason the FDA gave patent extensions to all

of the other makers of antidepressants in the past which meant lots of profits

to those companies. And this is exactly how we ended up with so many children

in trouble on antidepressants and with a severe black box warning being placed

upon all antidepressants on the market currently and ANY antidepressant to be

approved in the future.

 

So WHY on earth would the FDA approve of this process and make it so

financially advantageous to this company when we already know and

have such strong warnings on these drugs? This is clearly insanity at its

height!!!

 

Dr. Ann Blake Tracy, Executive Director,

International Coalition for Drug Awareness

_www.drugawareness.org_ (http://www.drugawareness.org) and author of

Prozac: Panacea or Pandora! Our Serotonin Nightmare and Help! I Can't Get Off My

Antidepressant! (800-280-0730)

 

_http://www.upi.com/HealthBusiness/view.php?StoryID=20060302-113704-9206r_

(http://www.upi.com/HealthBusiness/view.php?StoryID=20060302-113704-9206r)

 

Health Business

 

Forest gets Lexapro patent extension

 

NEW YORK, March 2 (UPI) -- Forest Laboratories said Thursday its

patent on anti-depressant Lexapro has been extended for nearly two and a half

years.

 

The company said it received a notice from the U.S. Patent and Trademark Office

that its patent covering Lexapro's composition of matter has been extended for

828 days.

 

That means the Lexapro patent is now in effect until Sept. 14, 2011, and until

March 14, 2012, with inclusion of six months' market exclusivity the drug maker

was granted for completing pediatric studies of Lexapro.

 

Lexapro is currently approved to treat major depressive disorder and

generalized anxiety disorder in adults.

 

Earlier this month reports said Forest Laboratories was substantially

reducing its Lexapro inventories due to slumping U.S. sales. Forest is

reportedly anticipating just under $2 billion in sales in fiscal 2006.

 

© Copyright 2006 United Press International, Inc. All Rights Reserved